 |
|
|
| |
A 52-Week Phase 3 Clinical Trial of Resmetirom
in 180 Patients With Well-Compensated NASH Cirrhosis
|
| |
| |
AASLD 2022 Nov 4-8
Stephen A. Harrison,1 Naim Alkhouri,2 Rebecca A. Taub,3 Guy W. Neff,4 Kris V. Kowdley,5 Mazen Noureddin6
1University of Oxford, United Kingdom & Pinnacle Clinical Research, San Antonio, TX; 2Arizona Liver Health, Tucson, AZ; 3Madrigal Pharmaceuticals, Conshohocken, PA; 4Covenant Metabolic Specialists, Sarasota, FL;
5Liver Institute Northwest, Seattle, WA; 6Houston Research Institute, Houston, TX
|
| |
|
|
|
|
|
